<DOC>
	<DOCNO>NCT01729156</DOCNO>
	<brief_summary>Background : Metformin treatment beneficial effect glucose lipid metabolism . Whereas general agreement blood glucose lower effect metformin result inhibition hepatic gluconeogenesis , less clear exactly drug lower blood triglyceride concentration . There indication enhances hepatic free fatty acid ( FFA ) oxidation thus diminish substrate reesterification resecretion very-low-density-lipoprotein ( VLDL ) triglyceride ( TG ) . However , liver easily accessible sample human data clinical effect metformin liver therefore lack . This may change due increase use positron emission tomography ( PET ) technique . Using PET isotope ( 11C 18F ) couple either palmitate fatty acid analogue , possible non-invasively measure hepatic fatty acid handling . Aim : To determine 3 month metformin treatment ( 1000 mg twice daily ) affect hepatic lipid metabolism patient newly diagnose type 2 diabetes . Design : Randomized , placebo control , double-blind parallel study patient receive either metformin placebo . A control group BMI age-matched healthy control receive metformin 3 month . Hypothesis : Metformin lower VLDL-TG secretion circulate triglyceride increase hepatic fatty acid oxidation</brief_summary>
	<brief_title>Effects Metformin Hepatic FFA Metabolism</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Newly diagnose type 2 diabetes ( &gt; 3 &lt; 12 month ) Age 5070 year BMI &lt; 40 Metformin treatment &gt; 6 month NASH ( non alcoholic steatohepatitis ) Cancer Anemia HbA1C &gt; 8.5 % Chronic acute pancreatitis Alcohol medicine abuse Allergy towards metformin Claustrophobia Severe obesity ( weight &gt; 130 kilogram )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Hepatic fatty acid oxidation</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Metformin</keyword>
</DOC>